Concepedia

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

Wen Wee, Hao Xie, Gerald Fetterly, Laura Pitzonka, Amy Whitworth, Charles LeVea, John H. Wilton, Krystin Mantione, Sarah A. Schihl, Grace K. Dy,

American Journal of Clinical Oncology · 2018 · 33 citations · 19 references

DOIFull text

Open access

Abstract

Dovitinib 300 mg daily is the recommended dose when combined with gemcitabine and capecitabine, achieving clinically relevant plasma concentrations. The study combination demonstrated encouraging efficacy signals in advanced pancreatic cancer.

References

19

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena et al. · New England Journal of Medicine · 2013 · 6.5K citations

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Malcolm J. Moore, David Goldstein, John Hamm et al. · Journal of Clinical Oncology · 2007 · 3.8K citations

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Oriol Casanovas, Daniel J. Hicklin, Gabriele Bergers et al. · Cancer Cell · 2005 · 1.6K citations · Full text

, , +9

Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

William Plunkett, Peng Huang, Yi-Zheng Xu et al. · PubMed · 1995 · 756 citations